Envisagenics Patents – Insights & Stats (Updated 2023)

Envisagenics has a total of 18 patents globally, out of which no patent has been granted. Of these 18 patents, more than 83% patents are active. United States of America seems to be the main focused R&D centre and also is the origin country of Envisagenics.

Envisagenics was founded in 2014. Envisagenics creates software for healthcare organizations. The company provides a drug discovery artificial intelligence platform. Envisagenics offers artificial intelligence and RNA splicing analytics for medicinal solutions.

Do read about some of the most popular patents of Envisagenics which have been covered by us in this article and also you can find Envisagenics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Envisagenics patent portfolio.

How many patents do the Founder and CEO of Envisagenics have?

The Founder Maria Luisa Pineda have 21 patent and Martin Akerman (Also CEO) have 25 patents.

How many patents does Envisagenics have?

Envisagenics has a total of 18 patents globally. These patents belong to 3 unique patent families. Out of 18 patents, 15 patents are active.

How Many Patents did Envisagenics File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantEnvisagenics Applications FiledEnvisagenics Patents Granted
20231
20221
20215
20206
20195

How many Envisagenics patents are Alive/Dead?

Worldwide Patents

How Many Patents did Envisagenics File in Different Countries?

Countries in which Envisagenics Filed Patents

CountryPatent
United States Of America3
Hong Kong (S.A.R.)3
Europe3
Canada2
Australia2
China2

Where are Research Centers of Envisagenics Patents Located?

The Research Centers of Envisagenics Patents is the United States of America.

Best Envisagenics Patents

WO2019226804A1 is the most popular patent in the Envisagenics portfolio. It has received 10 citations so far from companies like Genome International Corporation, Singleron (Nanjing) Biotechnologies.

Below is the list of most cited patents of Envisagenics:

Publication NumberCitation Count
WO2019226804A110
CN112912961A3
WO2020210537A13
US20210280275A11
CA3100607A11

What Percentage of Envisagenics US Patent Applications Were Granted?

Envisagenics (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0%.

Below are the key stats of Envisagenics patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Envisagenics?

Law FirmTotal ApplicationsSuccess Rate
Goodwin Procter Llp20%

What are Envisagenics key innovation segments?

What Technologies are Covered by Envisagenics?

The chart below distributes patents filed by Envisagenics in different countries on the basis of the technology protected in patents. It also represents the markets where Envisagenics thinks it’s important to protect particular technology inventions.

R&D Focus: How has Envisagenics search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Envisagenics?

Related Articles

Xiamen Easo Patents – Insights & Stats (Updated 2024)

Xiamen Easo has a total of 681 patents globally, out of which 536 have been granted. Of these 681 patents, more than 59% patents are active. China is where Xiamen Easo has filed the maximum number of patents, followed by United States of America and Europe (EPO). Parallelly, China seems

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.